143 related articles for article (PubMed ID: 36178283)
1. cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.
Semiz HS; Pala EE; Can B; Atag E; Gungor H; Sanci M
Turk Patoloji Derg; 2023; 39(1):55-63. PubMed ID: 36178283
[TBL] [Abstract][Full Text] [Related]
2. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
[TBL] [Abstract][Full Text] [Related]
3. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma.
Sawada M; Tsuda H; Kimura M; Okamoto S; Kita T; Kasamatsu T; Yamada T; Kikuchi Y; Honjo H; Matsubara O
Cancer Sci; 2003 Nov; 94(11):986-91. PubMed ID: 14611676
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
[TBL] [Abstract][Full Text] [Related]
5. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
6. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
[TBL] [Abstract][Full Text] [Related]
8. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
9. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
10. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
11. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
13. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
14. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
[TBL] [Abstract][Full Text] [Related]
16. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.
Schipf A; Mayr D; Kirchner T; Diebold J
Virchows Arch; 2008 Mar; 452(3):259-68. PubMed ID: 18193277
[TBL] [Abstract][Full Text] [Related]
18. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].
Scheer M; Prange W; Petmecky K; Schirmacher P; Zöller JE; Kübler AC
Mund Kiefer Gesichtschir; 2003 May; 7(3):138-45. PubMed ID: 12764679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]